Radius Health Stock Forecast, Price & News

9 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Radius Health in the last year. There are currently 6 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" Radius Health stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in RDUS, but not buy additional shares or sell existing shares.
View analyst ratings for Radius Health or view top-rated stocks.

Wall Street analysts have given Radius Health a "Hold" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Radius Health wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Radius Health is scheduled to release its next quarterly earnings announcement on Thursday, May 6th 2021.
View our earnings forecast for Radius Health.

Radius Health, Inc. (NASDAQ:RDUS) announced its quarterly earnings data on Thursday, February, 25th. The biopharmaceutical company reported ($0.46) earnings per share for the quarter, missing analysts' consensus estimates of ($0.39) by $0.07. The biopharmaceutical company earned $62.78 million during the quarter, compared to analysts' expectations of $59.16 million.
View Radius Health's earnings history.

Radius Health's stock was trading at $16.06 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, RDUS shares have increased by 21.4% and is now trading at $19.49.
View which stocks have been most impacted by COVID-19.

9 analysts have issued 12-month price objectives for Radius Health's stock. Their forecasts range from $14.00 to $33.00. On average, they expect Radius Health's share price to reach $24.60 in the next twelve months. This suggests a possible upside of 26.2% from the stock's current price.
View analysts' price targets for Radius Health or view top-rated stocks among Wall Street analysts.

Some companies that are related to Radius Health include ChemoCentryx (CCXI), Nektar Therapeutics (NKTR), PTC Therapeutics (PTCT), Apellis Pharmaceuticals (APLS), InnovAge (INNV), Insmed (INSM), ACADIA Pharmaceuticals (ACAD), Reata Pharmaceuticals (RETA), Karuna Therapeutics (KRTX), Arvinas (ARVN), Alkermes (ALKS), Pacira BioSciences (PCRX), MorphoSys (MOR), Organogenesis (ORGO) and Viela Bio (VIE).
View all of RDUS's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Radius Health investors own include NVIDIA (NVDA), Gilead Sciences (GILD), Amarin (AMRN), ACADIA Pharmaceuticals (ACAD), Exact Sciences (EXAS), Cara Therapeutics (CARA), OPKO Health (OPK), Portola Pharmaceuticals (PTLA), Micron Technology (MU) and Netflix (NFLX).

Radius Health trades on the NASDAQ under the ticker symbol "RDUS."

Radius Health's stock is owned by many different retail and institutional investors. Top institutional shareholders include Pacer Advisors Inc. (0.00%). Company insiders that own Radius Health stock include Anthony Rosenberg, Growth N V Biotech, James George Chopas, Joseph Francis Kelly, Target N V Biotech and Willard H Dere.
View institutional ownership trends for Radius Health.

RDUS stock was sold by a variety of institutional investors in the last quarter, including Pacer Advisors Inc..
View insider buying and selling activity for Radius Health or view top insider-selling stocks.

Shares of RDUS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of RDUS stock can currently be purchased for approximately $19.49.

Radius Health has a market capitalization of $913.96 million and generates $173.32 million in revenue each year. The biopharmaceutical company earns $-132,990,000.00 in net income (profit) each year or ($2.89) on an earnings per share basis.

Radius Health employs 310 workers across the globe.

The official website for Radius Health is www.radiuspharm.com.

Radius Health is headquartered at 950 WINTER STREET, WALTHAM MA, 02451.

Radius Health's mailing address is 950 WINTER STREET, WALTHAM MA, 02451. The biopharmaceutical company can be reached via phone at 617-551-4000 or via email at [email protected]